GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aptose Biosciences Inc (FRA:LTI) » Definitions » Additional Paid-In Capital

Aptose Biosciences (FRA:LTI) Additional Paid-In Capital : €74.12 Mil(As of Sep. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Aptose Biosciences Additional Paid-In Capital?


Aptose Biosciences's quarterly additional paid-in capital increased from Mar. 2024 (€72.81 Mil) to Jun. 2024 (€76.43 Mil) but then stayed the same from Jun. 2024 (€76.43 Mil) to Sep. 2024 (€74.12 Mil).

Aptose Biosciences's annual additional paid-in capital increased from Dec. 2021 (€56.35 Mil) to Dec. 2022 (€65.01 Mil) and increased from Dec. 2022 (€65.01 Mil) to Dec. 2023 (€66.16 Mil).


Aptose Biosciences Additional Paid-In Capital Historical Data

The historical data trend for Aptose Biosciences's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aptose Biosciences Additional Paid-In Capital Chart

Aptose Biosciences Annual Data
Trend May14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Additional Paid-In Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only 31.18 41.81 56.35 65.01 66.16

Aptose Biosciences Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 67.22 66.16 72.81 76.43 74.12

Aptose Biosciences Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

Aptose Biosciences Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Aptose Biosciences's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.


Aptose Biosciences Business Description

Traded in Other Exchanges
Address
251 Consumers Road, Suite 1105, Toronto, ON, CAN, M2J 4R3
Aptose Biosciences Inc is a clinical-stage biotechnology company committed to discovering and developing personalized therapies addressing unmet medical needs in oncology. The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities.

Aptose Biosciences Headlines

No Headlines